



Voltage-gated channels { calcium channels
sodium channels
potassium channels } have similar structure



Structure of Ca^{2+} / Na⁺ channels (I) [each subunit - 6 transmembrane domains]



→ Consists of 4 pseudosubunits [4 very similar domains linked together]

→ α (channel forming) + β (accessory) subunit structure

→ α subunit very large (> 2000 aa), β subunit smaller

→ Evolutionarily related to K^+ channel

- in K^+ channel, 4 of these

subunits join together



* The 4th transmembrane domain is charged and act as voltage sensor. When membrane potential changes, the 4th TM domain moves, opening & closing the channel.

Molecular Diversity Diversity is the rule, not the exception

- many diff subunit chains
- distinct tissue distributions

- Come together to form receptor / channel subtypes
- pharmacology determined by subunit composition

- Calcium channels, L, N, P, Q, R, T-types

L-type antagonists - useful CV drugs ~~if heart failure~~

N-, P-type antagonist - neurotoxins

- Benzodiazepine agonists (GABA_A receptors)

$\alpha 1$ selective : ~~hypnotics~~ hypnotics

$\alpha 2, \alpha 3, \alpha 5$ selective : anxiolytics


→ anti-anxiety drugs

Preview from Notesale.co.uk
Page 4 of 84

G-protein coupled receptors: also 7Tm receptor

- Historically, most important drug class
- 31 of top 100 drugs target GPCR
- Most diverse receptor class
- 1500 GPCR sequences in human genome
- 600 suitable drug targets, only 200 have known ligands

→ mostly monomeric, some dimeric though (metabotropic family)
 G-protein → membrane associated protein
 → sits on the inner phase of plasma membrane



* Agonist binding site in the centre of G-protein coupled receptor
 ↳ located ~~extra~~ extracellularly

G-protein binding domain - allow binding of G-protein




Diversity... → mostly caused by diversity in α subunit of G-protein

- As with ion channels, multiple subtypes
- muscarinic acetylcholine receptor M1-M5
- Adrenergic receptors $\alpha_1, \alpha_2, \beta_1, \beta_2$... (at least)

G-protein activation cycle:

Preview from Notesale.co.uk
 Page 6 of 84

α -subunit bound to GTP can now activate other target protein



G-protein has 3 subunits, α, β, γ
 α bound to GDP



GTP → GDP + P_i

α -subunit contains GTPase, hydrolyzing GTP into GDP + P_i

α -subunit without GTP has no activation effect, hence binds to β & γ again.

Affinity & Efficacy of a drug:

- Affinity (binding) (how tight)
- Efficacy = what it does once bound
 - Agonist: full efficacy
 - Antagonist: zero efficacy

Partial agonists lies between (Ariens & Stephenson 1950)

Homologous series - (similar drugs, but differ in length)

Maximum less than full agonist

can antagonise an agonist

↓
alkyltrimethylammonium drugs

↳ still activate the receptor but NOT as much as full agonist
↳ same mechanism as competitive antagonism


responses require affinity & efficacy

agonists have both

competitive ~~agonist~~ antagonist have affinity but no efficacy

Partial ~~agonist~~ agonists have affinity & some efficacy

Alkyltrimethylammonium drugs (agonist at muscarinic acetylcholine receptors)




R - butyl

- heptyl

- Decyl

* Partial agonists also produce a rightward shift in conc. response curve to a full agonist

Contraction of Guinea Pig Ileum



IMPORTANT

Full Agonist

- high affinity to active receptors (stabilizes it)
- low affinity to inactive receptors

Partial Agonist

- high affinity to active receptors
- low affinity to inactive receptors

Antagonist

- no affinity to active receptors
- equal affinity to inactive receptors
- equal affinity to active receptors
- equal affinity to inactive receptors

* receptors capable of spontaneous activation

* agonist stabilizes active receptor

Tone and Antagonists:

↳ competitive antagonists alone do not have effects (no intrinsic efficacy)

↳ tone: basal activity of a system

↳ antagonists antagonize endogenous mediators responsible for tone



* Atropine ↑ HR by blocking mAChR

Salivary Secretion:

(1) low secretion (tone)


(2) High secretion (tone)

↳ At receptor level, antagonist bind and do NOTHING




Cholinergic Transmission

- cholinergic = via ~~as~~ acetylcholine
- acetyl - which ↑ affinity to receptor



permanent +ve charge, necessary for interaction with receptors




VSCC - voltage sensitive Ca²⁺ channels

AChE - Acetylcholinesterase

↳ cleaves ester bond of ACh into acetate + choline

ACh receptor - can be nicotinic / muscarinic



- choline is recycled back into presynaptic terminal via a specific transporter [choline transporter] (sodium dependent)
- choline + acetate → synthesis ACh from choline + acetate

Acetylcholine receptors: (metabotropic)

- muscarinic: G-protein coupled, slow (5-15s)

- nicotinic: ligand-gated ion channel, fast transmission (1ms-1.5s) (ionotropic)

Acetylcholine Receptors

Nicotinic Receptors

NMTJ

CNS

Autonomic ganglia

Muscarinic Receptors

CNS

PNS

SNS

Xenopus oocytes : lifespan 20 years

- unfertilized eggs from Xenopus laevis (African clawed frog)
- injection $\Rightarrow$ DNA / RNA coding for protein of interest, it will be synthesised
- reliable : most proteins properly expressed
- very large (1mm), easy to handle, versatile, equipment relatively simple
- Every oocyte needs to be injected
- High-throughput screening difficult
- some endogenous proteins (proteins of the Xenopus)

optimum temperature for mammalian $\rightarrow 37^{\circ}\text{C}$

“ “ Xenopus $\rightarrow 18^{\circ}\text{C}$

Hence, Xenopus not 100% reliable for protein production

Mammalian Cell lines :

- $\hookrightarrow$ usually best for fidelity of expression
- $\hookrightarrow$ can be cultured in large batches - good for high-throughput
- $\hookrightarrow$ versatile: binding studies, ion flux experiments, imaging studies, electrophysiology
- $\hookrightarrow$ difficult to culture (expensive media)
- $\hookrightarrow$ require aseptic lab conditions
- $\hookrightarrow$ possible problems w/ endogenous proteins as they may interfere w/ desired proteins
- $\hookrightarrow$ Typically an immortalized cell

- cancer cell, cell w/ mutation / viral infection
- normal restrictions on cell division lost

- cell can divide $\left\{ \right.$ reproduce indefinitely


Eg: HEK 293, CHO cell, COS-7 (monkey)

African green monkey kidney cells immortalized with SV40 virus

$\hookrightarrow$ derived from human $\rightarrow$ chinese hamster ovary

Expression vector (Plasmid)

Embryonic kidney transformed w/ adenovirus



- Plasmid is placed w/ a strong promoter
- plasmid would be grown up in bacteria and also contains an antibiotic resistance genes - This allows selection for desired bacteria in culture.

Typical bacterial culture might yield several μg of plasmid DNA

Blood Pressure - 120/80 mmHg

Hypertension - ↑ diastolic, systolic, PP

Quantifying hypertension: severe > 160 mmHg
(diastolic) moderate 105-120 mmHg
mild 90-105 mmHg

* many CV diseases & renal diseases related to hypertension

Classification of Hypertension by aetiology:

- 1) Primary (essential / idiopathic) hypertension - unknown cause
- 2) Secondary hypertension - identified cause eg: polycystic renal disease
renal artery stenosis [narrowing of renal artery]
pheochromocytoma - tumour of adrenal medulla secretes adrenaline, causing ↑ BP

Consequences of Hypertension
Coronary artery disease (myocardial infarction)
Stroke
L cerebral haemorrhage
L thrombosis & thromboembolism

thrombosis - abnormal blood clot in blood vessels

Principles of Treatment: Blood pressure control by drugs

BP = CO x peripheral resistance

Basic principle: interfere w control mechanisms that do not compromise cardiovascular function


Typical Resistance Arteriole: Adrenaline & Vascular Tone:

Lifestyle modifications

- 1) lose weight
- 2) limit alcohol intake
- 3) regular exercise / activity
- 4) reduce sodium intake
- 5) maintain potassium intake
- 6) maintain calcium and magnesium intake
- 7) stop smoking!
- 8) reduce dietary fat & cholesterol





can change its diameter due to contraction and relaxation of smooth muscle



thiazide diuretics: main eg = bendroflumethiazide, ~~ethacrynic acid~~
 chlorthalidone (thiazide related)

↳ Act by inhibiting Na^+/Cl^- cotransporter in distal convoluted tubule



↳ ↑ NaCl passed to more distal segments

↳ ↓ difference in osmolality between urine & plasma

↳ ↓ less ability to reabsorb water in more distal portions

↳ similar effects as loop diuretics but milder effects & act at diff. locations of the kidney


Clinical use

- ↳ oedema due to heart failure → oedema shows up as cloudiness over the lungs as fluid obscures X-ray
- ↳ hypertension (lower doses)
- ↳ initial effects due to diuresis
- ↳ later, get vascular effects
- ↳ mild diuretics

Hypokalaemia: low K^+ levels

• major problem w/ loop diuretics, thiazides

- ↑ NaCl passed onto collecting duct increases Na^+ across principal cells
- ↑ lumen -ve potential leading to K^+ loss (function to reabsorb K^+)
- ↑ volume of urine: ↑ flushing of K^+ as it is sucked by -ve membrane potential of lumen



Potassium sparing diuretics:

General mechanism: decreases trans-epithelial cell Na^+ movement, decreases -ve lumen potential

main eg: spironolactone, amiloride, triamterene

Potassium sparing diuretics:

- ↳ weak diuretic action on their own
- ↳ usually used in combination w/ other diuretics
- ↳ spironolactone used in hyperaldosteronism
 - ↳ cirrhosis (failure to metabolize Alb)
 - ↳ Conn's syndrome (adrenal tumour)

Amiloride } Block Sodium channels in
 Triamterene } lumenal membrane

Spironolactone

↳ aldosterone antagonist (competitive)

↳ aldosterone ↑ sodium absorption by

↑ no. of Na^+/K^+ ATPase, ↑ no. of Na^+ channels

stimulating Na^+ channels via protein mediator


Antihypertensive drugs: Antagonists of adrenoceptors

Fight or flight response:

Sympathetic nerves - noradrenaline
adrenal medulla - adrenaline

blood vessels
heart
lungs
eye
bladder

GI tract
genitalia
salivary glands
sweat glands



Function of Adrenergic Receptors:

- | α_1 | α_2 | β_1 | β_2 |
|---|--|---|---|
| Gq
phospholipase C | G _i
adenylyl cyclase | G _s
adenylyl cyclase | G _s
adenylyl cyclase |
| ↓ | ↓ | ↓ | ↓ |
| <ul style="list-style-type: none"> • vasoconstriction, ↑BP • contract visceral smooth muscle <ul style="list-style-type: none"> ↳ bladder sphincter ↳ uterus ↳ iris radial muscle ↳ seminal tract ↳ pilomotor muscles • relax GI tract | <ul style="list-style-type: none"> • transmitter release • insulin release | <ul style="list-style-type: none"> • heart rate & force • release of renin • lipolysis • glycogenolysis | <ul style="list-style-type: none"> • bronchodilation • vasodilation (↓BP) • relax visceral smooth muscle • lipolysis • glycogenolysis • muscle tremor |

α_1
phenylephrine
oxymetazoline

α_2
clonidine
~~α2-methyl~~
α-methyl noradrenaline

β_1
dobutamine

β_2
salbutamol

~~metaxamine~~
methoxamine


isoprenaline

noradrenaline

adrenaline

Preview from Notesale.co.uk
Page 40 of 84

Drug - no therapeutic effects



Uses of α -adrenoreceptor antagonists:

Treatment of Pheochromocytoma

Pheochromocytoma - tumour of adrenal medulla
 - Secretes adrenaline erratically
 - episodes of severe hypertension

→ Phentolamine - used as treatment

→ phenoxylbenzamine used during surgery as precaution when removing adrenal tumour that may lead to release of excess adrenaline at a renal dose

α -adrenoreceptor antagonists as antihypertensive agents

Phentolamine - non-selective α -adrenoreceptor antagonists
 - unsuitable for treatment of hypertension

Prazosin - α_1 -selective adrenoreceptor antagonist


- used in treatment of hypertension
 - acts as inhibitory autoreceptors


→ α_2 - provide negative feedback to release of NA @ the heart

→ simultaneous blockade of α_1 & α_2 adrenoreceptors by phentolamine leads to unacceptable reflex tachycardia as autoinhibition of

noradrenaline prevented [no negative feedback as α_2 blocked]

→ Selective blockade of α_1 -adrenoreceptors by prazosin leads to acceptable reflex tachycardia





Hyperlipidaemias : high blood lipid content

- number of diff. forms
- diff disturbances in LDL, VLDL, cholesterol
- treated differently due to diversity of hyperlipidaemias

Lipid lowering drugs — Aim < $\begin{matrix} \text{reduce LDL} \\ \text{increase HDL} \end{matrix}$

↳ Approach varies w hyperlipidaemia

↳ statins

↳ ezetimibe

↳ fibrates

↳ exchange resins

↳ nicotinic acid

Dietary changes :


- ↓ saturated fat
- ↑ unsaturated fat
- ↑ fibre
- avoid trans fat & hydrogenated fats
- ↑ exercise level

Preview from Notesale.co.uk
Page 49 of 84

Statins → ~~Atorvastatin~~ Atorvastatin, Simvastatin

- competitively inhibits HMG-CoA reductase, rate limiting enzyme in production of cholesterol
- ↳ similar in structure to HMG-CoA

- reduces liver production of cholesterol
- lowered cholesterol leads to ~~removal~~ ↑ LDL receptors, ↑ removal LDL from plasma
- also ↑ HDL & ↓ triglycerides



Problems

- Myositis → muscle inflammation
- Rhabdomyolysis → muscle breakdown
- altered liver function tests
- Some cases, may cause liver failure

Ezetimibe

- inhibits intestinal cholesterol absorption by inhibiting specific cholesterol transporter in gut
- results in ↓ LDL, ↓ total cholesterol
- Co-administered with "statins" → gives dual inhibition of cholesterol absorption } synthesis
↓
intestinal tract ↓
 liver

Cholesterol Absorption in Intestine:



cholesterol transporter

ezetimibe (Zetia)

cholesterol

main remains [colestyramine]

erythromycin

bile acids can't be recycled to liver

Preview from Notesale.co.uk

Page 50 of 84

edge
the charge main
Anion Exchange Resins [cholestyramine] $\rightarrow$ bile acids can't be recycled to liver
L7 sequester bile acids in GT, bind to -ve charged bile acids
- reduce their absorption
bile acids can't be recycled to liver
emulsify fats

- reduce exogenous cholesterol absorption
- increase conversion of endogenous cholesterol to bile acids
- increase LDL receptors expression in liver cells $\rightarrow$ removal of LDL from plasma

Problems

Union exchange resins need to be taken into body in large quantities to obtain desired effect
 ↳ now rarely used

GIT upsets

- nausea, bloating, constipation or diarrhoea are common
- ↓ absorption of fat soluble vitamins, ~~drugs~~ fat soluble drugs
(A, D, E, K)
↓ eg:
warfarin

Heart as an Electrically controlled Pump

- SAN initiates cycle
- AVN relays to ventricles
- Purkinje fibres } Bundle of His spread impulse through ventricles

Surface electrocardiogram

- Compound AP from individual APs
- basis for diagnosis } treatment

P - atrial depolarisation

QRS - ventricular depolarisation

T - ventricular repolarisation

malfunctioning electrical system leads to poor pumping:

inadequate supply of blood to body

- lack of coordination of pumping or very fast rate leads to turbulence (risk factor for blood clots, stroke, heart attack)



↳ blood being pumped back & forth between atria & ventricles

cardiac arrhythmias / dysrhythmias: any disorder of heart rate / rhythm

↳ disruption of the normal electrical conduction system of the heart

dysrhythmia - disorganised rhythm

arrhythmia - absence of rhythm (more serious)



- ↓
- slow down pumping of heart
- atria contract at a higher rate than ventricle
- primarily leads to bradycardia

Preview from Notesale.co.uk
Page 52 of 84


Verapamil in Angina of Effort

- blockade of Ca^{2+} channels is use dependent
- more potent on heart than vascular smooth muscle
- Ca^{2+} channel blockade in myocardium reduces heart rate & cardiac output
- dilation of arterioles reduces cardiac afterload
- cardiac work & O_2 demand are reduced

Nifedipine in Angina of Effort


- blockade of Ca^{2+} ~~smooth~~ channels is NOT use-dependent
 - more potent on vascular smooth muscle than heart
 - dilation of arterioles reduce cardiac workload
 - dilation of capacitance veins reduces cardiac preload
 - cardiac work and O_2 demand ↓
- } Similar to ~~vaso~~ GTN

Drugs used to treat Angina and Myocardial Infarction:



Leukotriene Antagonists

Consequence of taking aspirin → can lead



Leukotrienes

produced by mast cells, eosinophils, basophils and macrophages

important mediator in asthma

agonist at ~~cytotoxic~~ ^{cystenyl} - leukotriene (cysLT) receptors

contracts bronchial smooth muscle

stimulates mucus secretion

increases microvascular permeability (walls of blood vessel open up, allow entry of leukocyte infiltration)

Competitive antagonists at cysLT receptors

montelukast and zafirlukast

given orally

Add-on, prophylactic therapy in mild to moderate asthma

reduces exercise-induced asthma

reduces aspirin-induced asthma

[if aspirin taken in excess, there may be excess leukotriene production → asthma]

aspirin is very dangerous for asthma

Unwanted Effects

↳ abdominal pain, nausea

↳ headache

↳ hepatotoxicity (Zafirlukast)

as all the arachidonic acids are channelled for leukotriene production

Preview from Notesale.co.uk
Page 80 of 84